Baird Downgrades Immunovant to Neutral, Announces $10 Price Target
Baird analyst Brian Skorney downgrades Immunovant (NASDAQ:IMVT) from Outperform to Neutral and announces $10 price target.
61 Biggest Movers From Yesterday
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.
Mid-Afternoon Market Update: Nasdaq Gains 50 Points; Marin Software Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.02% to 34,941.69 while the NASDAQ rose 0.37% to 14,727.42. The S&P also rose, gaining 0.10% to 4,399.45.
Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.35% to 35,058.26 while the NASDAQ rose 0.52% to 14,748.83. The S&P also rose, gaining 0.39% to 4,412.29.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program.
Immunovant Stock Plunges On $200M Equity Investment From Roivant To Support IMVT-1401 Development
Immunovant Inc (NASDAQ:IMVT) has received a $200 million strategic investment from Roivant Sciences that the Company will use to advance IMVT-1401 in multiple…
Biotech Losers In 2021 That Could Bounce Big In The Second Half
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as a bargain buy. A lot of background research should go into the stock, company pipeline, cash runway, and other factors before an investment decision can be made.
Credit Suisse Maintains Neutral on Immunovant, Lowers Price Target to $12
Credit Suisse analyst Tiago Fauth maintains Immunovant (NASDAQ:IMVT) with a Neutral and lowers the price target from $26 to $12.